comscoreBone Health

Bone Health

19 Research news
 
 
Article
Research Pinpoints Which Women Benefit From Bisphosphonates After Early-Stage Disease

A large study has found that bisphosphonates reduce the risk of distant breast cancer recurrence in postmenopausal women.

Jan 28, 2014 | Diagnosis, Risk Factors and Bone Health
 
Article
Prolia Reduces Recurrence Risk of Hormone-Receptor-Positive Disease in Women Taking Aromatase Inhibitors

A study has found that Prolia improved disease-free survival for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.

 
Article
Xgeva Slightly Better Than Zometa at Reducing Breast Cancer Bone Complications

Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones.

 
Article
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor

The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.

 
Article
Zometa Can Help Reduce Recurrence Risk of Hormone-Receptor-Positive Disease

Results from three studies all suggest that Zometa can help reduce the risk of cancer recurrence when it's started right after surgery to treat hormone-receptor-positive early-stage breast cancer in postmenopausal and older premenopausal women.

Dec 10, 2011 | Diagnosis and Bone Health
 
Article
Oral Bisphosphonates Don't Seem to Reduce Recurrence Risk

Two studies found that two oral bisphosphonates didn't reduce recurrence risk for women diagnosed with early-stage breast cancer.

Dec 12, 2011 | Diagnosis and Bone Health
 
Article
Zometa Seems to Improve Response to Chemotherapy

Research suggests that Zometa, a medicine used to strengthen bones, may slow breast cancer growth.

Dec 15, 2008 | Diagnosis, Chemotherapy and Bone Health
 
Article
Xgeva Better Than Zometa at Reducing Risk of Bone Problems in Women With Metastatic Disease

Research suggests that Xgeva is better than Zometa at reducing the risk of bone complication and improves quality of life more in women diagnosed with metastatic breast cancer that has spread to the bones.

 
Article
Experimental Bone Medicine May Lower Risk

A new selective estrogen receptor modulator (SERM) called Oporia (chemical name: lasofoxifene) has been shown to improve bone health and reduce the risk of breast cancer, especially hormone-receptor-positive breast cancer, in post-menopausal women.

Dec 11, 2008 | Bone Health
 
Article
Zometa Before Surgery Doesn't Seem to Have Benefits

Research shows that Zometa (chemical name: zoledronic acid) doesn't destroy or slow the growth of breast cancer cells when given before surgery to post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.

 
Article
All Bisphosphonates Reduce Recurrence Risk the Same Amount

All bisphosphonates seem to offer the same recurrence risk reduction benefits.

Jun 9, 2015 | Diagnosis and Bone Health
 
Article
Prolia Dramatically Lowers Risk of Breaking Bones in Women Taking Aromatase Inhibitors

A study found that Prolia reduced the risk of breaking a bone by 50% in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who were taking an aromatase inhibitor.

 
Article
Zometa Plus Femara Seems Better Than Tamoxifen for Premenopausal Women With Hormone-Receptor-Positive Breast Cancer, but Causes More Side Effects

The combination of Zometa and Femara after surgery offered better disease-free survival than tamoxifen for premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer, but caused more side effects.

 
Article
More Than 2 Years of Bisphosphonates for Early-Stage Breast Cancer Doesn't Offer More Benefits

Receiving 3 to 5 years of bisphosphonate treatment after surgery and chemotherapy for early-stage breast cancer doesn’t improve survival any more than receiving 2 years of bisphosphonate treatment.

Jul 2, 2021 | Diagnosis and Bone Health
 
Article
Research Suggests Women With Breast Cancer That Has Spread to Bone Can Safely Receive Zometa Less Often

A study suggests that after a year, women with bone metastases can get Zometa every 12 weeks instead of every 4 weeks and still get the same benefits from the medicine, while reducing their risk of side effects.

 
Article
Xgeva More Likely to Cause Osteonecrosis of the Jaw in Women Diagnosed With Advanced-Stage Breast Cancer

Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.

 
Article
Zometa Every 3 Months Seems as Good as Every Month for Women With Bone Metastases After First Year of Treatment

After a year of standard treatment, women with bone metastases can get Zometa every 12 weeks instead of 4 and get the same benefits from the medicine.

 
Article
Two Studies Show Bisphosphonates Don't Reduce Breast Cancer Risk

Two randomized studies found that 3 to 4 years of treatment with either Fosamax or zoledronic acid doesn't seem to reduce breast cancer risk in postmenopausal women.

Aug 14, 2014 | Bone Health and Risk Factors
 
Article
FDA Warning: Reclast May Cause Severe Kidney Problems

On Sept. 1, 2011 the U.S. Food and Drug Administration warned doctors and patients that Reclast may cause severe kidney problems.